190 related articles for article (PubMed ID: 20201816)
1. Blockade of the cannabinoid CB1 receptor and alcohol dependence: preclinical evidence and preliminary clinical data.
Maccioni P; Colombo G; Carai MA
CNS Neurol Disord Drug Targets; 2010 Mar; 9(1):55-9. PubMed ID: 20201816
[TBL] [Abstract][Full Text] [Related]
2. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol.
López-Moreno JA; González-Cuevas G; Navarro M
Neurobiol Dis; 2007 Feb; 25(2):274-83. PubMed ID: 17067804
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence.
Colombo G; Orrù A; Lai P; Cabras C; Maccioni P; Rubio M; Gessa GL; Carai MA
Mol Neurobiol; 2007 Aug; 36(1):102-12. PubMed ID: 17952655
[TBL] [Abstract][Full Text] [Related]
4. Endocannabinoid system and alcohol addiction: pharmacological studies.
Colombo G; Serra S; Vacca G; Carai MA; Gessa GL
Pharmacol Biochem Behav; 2005 Jun; 81(2):369-80. PubMed ID: 15939463
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats.
Fattore L; Spano M; Melis V; Fadda P; Fratta W
Br J Pharmacol; 2011 Aug; 163(7):1550-62. PubMed ID: 21518339
[TBL] [Abstract][Full Text] [Related]
6. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant.
Justinova Z; Munzar P; Panlilio LV; Yasar S; Redhi GH; Tanda G; Goldberg SR
Neuropsychopharmacology; 2008 Nov; 33(12):2870-7. PubMed ID: 18305459
[TBL] [Abstract][Full Text] [Related]
7. Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.
Le Foll B; Forget B; Aubin HJ; Goldberg SR
Addict Biol; 2008 Jun; 13(2):239-52. PubMed ID: 18482433
[TBL] [Abstract][Full Text] [Related]
8. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats.
Gessa GL; Serra S; Vacca G; Carai MA; Colombo G
Alcohol Alcohol; 2005; 40(1):46-53. PubMed ID: 15582988
[TBL] [Abstract][Full Text] [Related]
9. Drug addiction.
Justinova Z; Panlilio LV; Goldberg SR
Curr Top Behav Neurosci; 2009; 1():309-46. PubMed ID: 21104390
[TBL] [Abstract][Full Text] [Related]
10. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats.
Colombo G; Vacca G; Serra S; Carai MA; Gessa GL
Eur J Pharmacol; 2004 Sep; 498(1-3):119-23. PubMed ID: 15363985
[TBL] [Abstract][Full Text] [Related]
11. Cannabinoid CB(1) receptor antagonist rimonabant attenuates reinstatement of ketamine conditioned place preference in rats.
Li F; Fang Q; Liu Y; Zhao M; Li D; Wang J; Lu L
Eur J Pharmacol; 2008 Jul; 589(1-3):122-6. PubMed ID: 18534572
[TBL] [Abstract][Full Text] [Related]
12. Rimonabant: the first therapeutically relevant cannabinoid antagonist.
Carai MA; Colombo G; Gessa GL
Life Sci; 2005 Sep; 77(19):2339-50. PubMed ID: 15935395
[TBL] [Abstract][Full Text] [Related]
13. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice.
Vinod KY; Yalamanchili R; Thanos PK; Vadasz C; Cooper TB; Volkow ND; Hungund BL
Synapse; 2008 Aug; 62(8):574-81. PubMed ID: 18509854
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats.
Cippitelli A; Bilbao A; Hansson AC; del Arco I; Sommer W; Heilig M; Massi M; Bermúdez-Silva FJ; Navarro M; Ciccocioppo R; de Fonseca FR;
Eur J Neurosci; 2005 Apr; 21(8):2243-51. PubMed ID: 15869521
[TBL] [Abstract][Full Text] [Related]
15. Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys.
Schindler CW; Redhi GH; Vemuri K; Makriyannis A; Le Foll B; Bergman J; Goldberg SR; Justinova Z
Neuropsychopharmacology; 2016 Aug; 41(9):2283-93. PubMed ID: 26888056
[TBL] [Abstract][Full Text] [Related]
16. An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives.
Fattore L; Spano MS; Deiana S; Melis V; Cossu G; Fadda P; Fratta W
Brain Res Rev; 2007 Jan; 53(1):1-16. PubMed ID: 16839608
[TBL] [Abstract][Full Text] [Related]
17. Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
Doggrell SA
Expert Opin Pharmacother; 2005 Oct; 6(12):2141-4. PubMed ID: 16197364
[No Abstract] [Full Text] [Related]
18. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716).
Cohen C; Perrault G; Griebel G; Soubrié P
Neuropsychopharmacology; 2005 Jan; 30(1):145-55. PubMed ID: 15292905
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.
Soyka M; Koller G; Schmidt P; Lesch OM; Leweke M; Fehr C; Gann H; Mann KF;
J Clin Psychopharmacol; 2008 Jun; 28(3):317-24. PubMed ID: 18480689
[TBL] [Abstract][Full Text] [Related]
20. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats.
Lallemand F; De Witte P
Alcohol; 2006 Jul; 39(3):125-34. PubMed ID: 17127132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
